Lifecore Biomedical, Inc. (NASDAQ:LFCR) Q1 2025 Earnings Call Transcript
Operator: Good morning, and thank you for joining Lifecore's Fiscal 2025 First Quarter Earnings Call. During the presentation, all participants will be in a listen-only mode.
Lifecore Biomedical Inc. (LFCR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Wynnefield Capital Nelson Obus | 4,918,979 | $25,234,362 | -1% | 11.34% |
| 2. | Legion Partners Asset Management Ted White And Christopher Kiper | 2,968,409 | $15,227,938 | +1% | 4.69% |
| 3. | Greenhaven Road Investment Management Scott Stewart Miller | 2,216,124 | $11,368,716 | +4% | 5.26% |
| 4. | 325 Capital Michael Braner, Daniel Friedberg And Anil Shrivastava | 1,340,598 | $6,877,268 | 2.88% | |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 300,120 | $1,539,617 | +88% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.10 | 169,753 | Large Shareholder | 2,607,433 | 2024-10-03 | Filing | |
| $4.10 | 122,930 | Large Shareholder | 2,095,783 | 2024-10-03 | Filing | |
| $4.10 | 152,102 | Large Shareholder, Director | 319,286 | 2024-10-03 | Filing | |
| $4.10 | 1,311,312 | Large Shareholder, Director | 4,084,268 | 2024-10-03 | Filing | |
| $7.97 | 282,486 | Large Shareholder | 2,438,180 | 2022-11-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.36 | 9,239 | Officer | 58,929 | 2018-05-09 | Filing | |
| $13.85 | 163 | Officer | 68,168 | 2018-04-25 | Filing | |
| $13.86 | 1,132 | Officer | 68,331 | 2018-04-20 | Filing | |
| $13.88 | 3,499 | Officer | 69,463 | 2018-04-19 | Filing | |
| $13.92 | 12,179 | Officer | 72,962 | 2018-04-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,755,161 | $10,864,447 | 7.07% | |
| 2. | 1,350,567 | $8,360,009 | 0% | |
| 3. | 788,702 | $4,882,066 | 0% | |
| 4. | 599,300 | $3,709,667 | 0% | |
| 5. | 497,204 | $3,077,693 | 0.22% |
News See All
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Q4 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the Lifecore Biomedical Q4 and Full Year 2024 Earnings Call. At this time all participants are in a listen-only mode.
Laughing Water Capital is Waiting for an Investor Update from Lifecore Biomedical (LFCR)
Laughing Water Capital, an investment management company, released its second-quarter 2024 investor letter. A copy of the letter can be downloaded here.
Cove Street Capital Sold its Holding in Lifecore Biomedical (LFCR)
Investment management company Cove Street Capital recently released its “Small Cap Value Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here.
Hidden Gems: Unveiling the 10 Stocks on Hedge Funds' Radar
The US market sustained strong performance in the first quarter of 2024 as the S&P Index increased by 10.6%, continuing its momentum from the previous quarter.
Here’s Why Laughing Water Capital Invested in Lifecore Biomedical (LFCR)
Laughing Water Capital, an investment management company, released its first-quarter 2024 investor letter. A copy of the same can be downloaded here.
What Made White Falcon Hold Lifecore Biomedical (LFCR)?
White Falcon Capital Management, an investment fund manager, released its first quarter 2024 investor letter. A copy of the same can be downloaded here.
Do You Believe in the Upside Trajectory of Lifecore Biomedical (LFCR)?
Investment management company Cove Street Capital recently released its “Small Cap Value Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here.
Should You Hold Lifecore Biomedical (LFCR) for Long Term?
Laughing Water Capital, an investment management company, released its fourth-quarter 2023 investor letter. A copy of the same can be downloaded here.
Here's Why Cove Street Capital Reduced its Position in Lifecore Biomedical (LFCR)
Investment management company Cove Street Capital recently released its “Small Cap Value Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here.
Billionaire Hedge Funds
